EOLS
Evolus, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 651.82K | $5.21M | n/a | n/a |
| Q2 2026 | 63 | +6 | 23.25M | $161.16M | +10 | −4 |
| Q1 2026 | 59 | -7 | 18.93M | $77.97M | +3 | −10 |
| Q4 2025 | 66 | -1 | 24.04M | $159.85M | n/a | −1 |
| Q3 2025 | 17 | -1 | 17.27M | $106.03M | n/a | −1 |
| Q2 2025 | 15 | 0 | 14.12M | $130.04M | +1 | −1 |
| Q1 2025 | 12 | +2 | 7.19M | $86.49M | +2 | n/a |
| Q4 2024 | 10 | -1 | 6.42M | $70.90M | n/a | −1 |
| Q3 2024 | 10 | 0 | 4.64M | $75.21M | +1 | −1 |
| Q2 2024 | 10 | n/a | 4.38M | $47.51M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.18M | n/a | $38.54M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 2 | The Vanguard Group ✦ (passive) | 3.32M | n/a | $30.56M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Millennium Management ✦ | 1.48M | +6.6% | $13.66M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 1.41M | +1.7% | $12.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.23M | -2.4% | $11.35M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 957.74K | +9.2% | $8.82M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 581.86K | +135.1% | $5.36M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 341.40K | +318.4% | $3.14M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 164.02K | +9.0% | $1.51M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 10 | Adage Capital Partners ✦ | 128.40K | -73.6% | $1.18M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 123.86K | -35.4% | $1.14M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 71.27K | +6.8% | $656,350 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 13 | Marshall Wace ✦ | 67.85K | New | $624,860 | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 56.32K | +3.1% | $519,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 2.42K | n/a | $22,246 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $624,860 | 0.0% |
Exited
| Soros Fund Management | $11.98M | was 0.3% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 45.63M shares, $187.01M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 105.11K sh · $950,019
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology